Nicolas A Menzies1, Sourya Shrestha2, Andrea Parriott3, Suzanne M Marks4, Andrew N Hill4, David W Dowdy2, Priya B Shete5, Ted Cohen6, Joshua A Salomon7. 1. From the Harvard T.H. Chan School of Public Health, Boston, MA. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 3. Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA. 4. Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA. 5. Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA. 6. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT. 7. Department of Medicine, Stanford University, Palo Alto, CA.
Abstract
BACKGROUND: Effective targeting of latent tuberculosis infection (LTBI) treatment requires identifying those most likely to progress to tuberculosis (TB). We estimated the potential health and economic benefits of diagnostics with improved discrimination for LTBI that will progress to TB. METHODS: A base case scenario represented current LTBI testing and treatment services in the United States in 2020, with diagnosis via. interferon-gamma release assay (IGRA). Alternative scenarios represented tests with higher positive predictive value (PPV) for future TB but similar price to IGRA, and scenarios that additionally assumed higher treatment initiation and completion. We predicted outcomes using multiple transmission-dynamic models calibrated to different geographic areas and estimated costs from a societal perspective. RESULTS: In 2020, 2.1% (range across model results: 1.1%-3.4%) of individuals with LTBI were predicted to develop TB in their remaining lifetime. For IGRA, we estimated the PPV for future TB as 1.3% (0.6%-1.8%). Relative to IGRA, we estimated a test with 10% PPV would reduce treatment volume by 87% (82%-94%), reduce incremental costs by 30% (15%-52%), and increase quality-adjusted life years by 3% (2%-6%). Cost reductions and health improvements were substantially larger for scenarios in which higher PPV for future TB was associated with greater initiation and completion of treatment. CONCLUSIONS: We estimated that tests with better predictive performance would substantially reduce the number of individuals treated to prevent TB but would have a modest impact on incremental costs and health impact of TB prevention services, unless accompanied by greater treatment acceptance and completion.
BACKGROUND: Effective targeting of latent tuberculosis infection (LTBI) treatment requires identifying those most likely to progress to tuberculosis (TB). We estimated the potential health and economic benefits of diagnostics with improved discrimination for LTBI that will progress to TB. METHODS: A base case scenario represented current LTBI testing and treatment services in the United States in 2020, with diagnosis via. interferon-gamma release assay (IGRA). Alternative scenarios represented tests with higher positive predictive value (PPV) for future TB but similar price to IGRA, and scenarios that additionally assumed higher treatment initiation and completion. We predicted outcomes using multiple transmission-dynamic models calibrated to different geographic areas and estimated costs from a societal perspective. RESULTS: In 2020, 2.1% (range across model results: 1.1%-3.4%) of individuals with LTBI were predicted to develop TB in their remaining lifetime. For IGRA, we estimated the PPV for future TB as 1.3% (0.6%-1.8%). Relative to IGRA, we estimated a test with 10% PPV would reduce treatment volume by 87% (82%-94%), reduce incremental costs by 30% (15%-52%), and increase quality-adjusted life years by 3% (2%-6%). Cost reductions and health improvements were substantially larger for scenarios in which higher PPV for future TB was associated with greater initiation and completion of treatment. CONCLUSIONS: We estimated that tests with better predictive performance would substantially reduce the number of individuals treated to prevent TB but would have a modest impact on incremental costs and health impact of TB prevention services, unless accompanied by greater treatment acceptance and completion.
Authors: Rosa Sloot; Maarten F Schim van der Loeff; Peter M Kouw; Martien W Borgdorff Journal: Am J Respir Crit Care Med Date: 2014-11-01 Impact factor: 21.405
Authors: Timothy R Sterling; James Bethel; Stefan Goldberg; Paul Weinfurter; Lourdes Yun; C Robert Horsburgh Journal: Am J Respir Crit Care Med Date: 2006-01-19 Impact factor: 21.405
Authors: Sourya Shrestha; Andrea Parriott; Nicolas A Menzies; Priya B Shete; Andrew N Hill; Suzanne M Marks; David W Dowdy Journal: Ann Am Thorac Soc Date: 2020-12
Authors: Molebogeng X Rangaka; Katalin A Wilkinson; Judith R Glynn; Daphne Ling; Dick Menzies; Judith Mwansa-Kambafwile; Katherine Fielding; Robert J Wilkinson; Madhukar Pai Journal: Lancet Infect Dis Date: 2011-08-16 Impact factor: 25.071
Authors: Gillian D Sanders; Peter J Neumann; Anirban Basu; Dan W Brock; David Feeny; Murray Krahn; Karen M Kuntz; David O Meltzer; Douglas K Owens; Lisa A Prosser; Joshua A Salomon; Mark J Sculpher; Thomas A Trikalinos; Louise B Russell; Joanna E Siegel; Theodore G Ganiats Journal: JAMA Date: 2016-09-13 Impact factor: 56.272
Authors: Lynn E Sosa; Gibril J Njie; Mark N Lobato; Sapna Bamrah Morris; William Buchta; Megan L Casey; Neela D Goswami; MaryAnn Gruden; Bobbi Jo Hurst; Amera R Khan; David T Kuhar; David M Lewinsohn; Trini A Mathew; Gerald H Mazurek; Randall Reves; Lisa Paulos; Wendy Thanassi; Lorna Will; Robert Belknap Journal: MMWR Morb Mortal Wkly Rep Date: 2019-05-17 Impact factor: 17.586
Authors: Timothy R Sterling; Gibril Njie; Dominik Zenner; David L Cohn; Randall Reves; Amina Ahmed; Dick Menzies; C Robert Horsburgh; Charles M Crane; Marcos Burgos; Philip LoBue; Carla A Winston; Robert Belknap Journal: MMWR Recomm Rep Date: 2020-02-14
Authors: Nicolas A Menzies; Nicole Swartwood; Christian Testa; Yelena Malyuta; Andrew N Hill; Suzanne M Marks; Ted Cohen; Joshua A Salomon Journal: Epidemiology Date: 2021-01 Impact factor: 4.860